{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:15:40Z","timestamp":1789168540766,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"8108","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2026,4,2]]},"DOI":"10.1038\/s41586-025-10026-w","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T16:02:35Z","timestamp":1765987355000},"page":"174-180","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Mazdutide versus placebo in Chinese adults with type 2 diabetes"],"prefix":"10.1038","volume":"652","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1064-1261","authenticated-orcid":false,"given":"Dalong","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3267-9292","authenticated-orcid":false,"given":"Jiajun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanqing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8549-4374","authenticated-orcid":false,"given":"Shuangling","family":"Xiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengwei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifeng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bimin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2665-4072","authenticated-orcid":false,"given":"Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengtai","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3793-5350","authenticated-orcid":false,"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8720-7140","authenticated-orcid":false,"given":"Lei","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of\u00a0the DREAMS-1 Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"10026_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ijcard.2019.02.030","volume":"291","author":"A Avogaro","year":"2019","unstructured":"Avogaro, A. & Fadini, G. P. Microvascular complications in diabetes: a growing concern for cardiologists. Int. J. Cardiol. 291, 29\u201335 (2019).","journal-title":"Int. J. Cardiol."},{"key":"10026_CR2","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies, M. J. et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 45, 2753\u20132786 (2022).","journal-title":"Diabetes Care"},{"key":"10026_CR3","unstructured":"International Diabetes Federation. IDF Diabetes Atlas 11th edn (IDF, 2025)."},{"key":"10026_CR4","doi-asserted-by":"publisher","first-page":"e1089","DOI":"10.1016\/S2468-2667(24)00250-0","volume":"9","author":"Y Xu","year":"2024","unstructured":"Xu, Y. et al. Diabetes in China part 1: epidemiology and risk factors. Lancet Public Health 9, e1089\u2013e1097 (2024).","journal-title":"Lancet Public Health"},{"key":"10026_CR5","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1001\/jama.2021.22208","volume":"326","author":"L Wang","year":"2021","unstructured":"Wang, L. et al. Prevalence and treatment of diabetes in China, 2013\u20132018. JAMA 326, 2498\u20132506 (2021).","journal-title":"JAMA"},{"key":"10026_CR6","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.ahj.2013.07.012","volume":"166","author":"SP Marso","year":"2013","unstructured":"Marso, S. P. et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am. Heart J. 166, 823\u2013830 (2013).","journal-title":"Am. Heart J."},{"key":"10026_CR7","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/dmrr.2810","volume":"32","author":"J Jendle","year":"2016","unstructured":"Jendle, J. et al. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. Diabetes Metab. Res. Rev. 32, 776\u2013790 (2016).","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10026_CR8","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","volume":"5","author":"C Sorli","year":"2017","unstructured":"Sorli, C. et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 5, 251\u2013260 (2017).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10026_CR9","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S0140-6736(21)01324-6","volume":"398","author":"J Rosenstock","year":"2021","unstructured":"Rosenstock, J. et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 398, 212 (2021).","journal-title":"Lancet"},{"key":"10026_CR10","doi-asserted-by":"publisher","unstructured":"Chinese Diabetes Society. Guideline for the prevention and treatment of diabetes mellitus in China (2024 edition). Chin. J. Diabetes https:\/\/doi.org\/10.3760\/cma.j.cn115791-20241203-00705 (2025).","DOI":"10.3760\/cma.j.cn115791-20241203-00705"},{"key":"10026_CR11","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.2337\/dc22-S002","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2022","unstructured":"American Diabetes Association Professional Practice Committee. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes\u20142022. Diabetes Care 45, S17\u2013S38 (2022).","journal-title":"Diabetes Care"},{"key":"10026_CR12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S2213-8587(22)00349-7","volume":"11","author":"AJ Scheen","year":"2023","unstructured":"Scheen, A. J. & Lef\u00e8bvre, P. J. Glucagon, from past to present: a century of intensive research and controversies. Lancet Diabetes Endocrinol. 11, 129\u2013138 (2023).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10026_CR13","doi-asserted-by":"publisher","first-page":"160","DOI":"10.2337\/dc23-1287","volume":"47","author":"B Zhang","year":"2024","unstructured":"Zhang, B. et al. Efficacy and safety of mazdutide in Chinese patients with type 2 diabetes: a randomised, double-blind, placebo-controlled phase 2 trial. Diabetes Care 47, 160\u2013168 (2024).","journal-title":"Diabetes Care"},{"key":"10026_CR14","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","volume":"12","author":"CW le Roux","year":"2024","unstructured":"le Roux, C. W. et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 12, 162\u2013173 (2024).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10026_CR15","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","volume":"402","author":"J Rosenstock","year":"2023","unstructured":"Rosenstock, J. et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet 402, 529\u2013544 (2023).","journal-title":"Lancet"},{"key":"10026_CR16","doi-asserted-by":"publisher","unstructured":"Expert Group for Expert Consensus on weight management for type 2 diabetes mellitus. Experts consensus on weight management for type 2 diabetes mellitus (2024 edition). Int. J. Endocrinol. Metab. https:\/\/doi.org\/10.3760\/cma.j.cn121383-20240514-00022 (2024).","DOI":"10.3760\/cma.j.cn121383-20240514-00022"},{"key":"10026_CR17","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1056\/NEJMoa2411528","volume":"392","author":"J Li","year":"2025","unstructured":"Li, J. et al. Once-weekly mazdutide in Chinese adults with obesity or overweight. N. Engl. J. Med. 392, 2215\u20132225 (2025).","journal-title":"N. Engl. J. Med."},{"key":"10026_CR18","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.cell.2015.01.012","volume":"160","author":"RJ Perry","year":"2015","unstructured":"Perry, R. J. et al. Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. Cell 160, 745\u2013758 (2015).","journal-title":"Cell"},{"key":"10026_CR19","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.2337\/dc22-S006","volume":"45","author":"American Diabetes Association Professional Practice Committee and American Diabetes Association Professional Practice Committee","year":"2022","unstructured":"American Diabetes Association Professional Practice Committee. Glycemic targets: Standards of Medical Care in Diabetes\u20142022. Diabetes Care 45, S83\u2013S96 (2022).","journal-title":"Diabetes Care"},{"key":"10026_CR20","unstructured":"ICH. ICH Harmonised Guideline: Addendum on estimands and sensitivity analysis in clinical trials. ICH E9(R1) (ICH, 2019)."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-10026-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-10026-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-10026-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T11:07:18Z","timestamp":1775041638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-10026-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":20,"journal-issue":{"issue":"8108","published-print":{"date-parts":[[2026,4,2]]}},"alternative-id":["10026"],"URL":"https:\/\/doi.org\/10.1038\/s41586-025-10026-w","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"16 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.Z., H.\u2009Cai and H.J. serve as consultants to Innovent Biologics. F.X., H.D., H.L., L.L., Yue Li, Q.M. and L.Q. are employees of Innovent Biologics. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}